Last updated: July 17, 2026
Oxycodone and Aspirin (Combination Drug) Investment Scenario and Patent/Regulatory Fundamentals (US and Key Markets)
Oxycodone and aspirin is a fixed-dose combination product that has long commercial history but faces structural headwinds from opioid regulatory tightening, generic penetration, and supply-chain and labeling constraints tied to aspirin-containing analgesics. Investment attractiveness is therefore driven less by “new IP-led growth” and more by: (1) whether any brand-grade or protected combinations remain in force in the US and specific ex-US markets, (2) the depth and durability of patent or exclusivity coverage against new ANDA entrants, and (3) near-term revenue resilience versus enforced opioid-risk management and substitution pressures.
Because “oxycodone and aspirin” includes multiple strengths and brand/formulation variants, investment assessment must be anchored to the exact marketed product(s), Orange Book listings, and active litigation. Without the specific NDC/label and US innovator identity, this cannot be completed with patent-expiration precision.
What patents protect oxycodone and aspirin combination products?
Featured snippet answer: Patent coverage for oxycodone/aspirin combinations (when present) typically clusters around formulation/combination tablets, specific strength/dose forms, controlled-release variants (if any), manufacturing/process, and method-of-use dosing regimens. In practice, many oxycodone/aspirin products in the US are already generic, so the investable question is whether any particular innovator SKU still has unexpired patents or exclusivity that can block ANDA approval or generic launch.
How to map the patent estate for oxycodone/aspirin (what to check)
For any marketed fixed-dose combination tablet of oxycodone (opioid) plus aspirin (NSAID), the investable patent estate is usually assessed across:
- Composition of matter for the specific combination or salt form (rare for long-established combinations, common for newer delivery technologies).
- Formulation patents for tablet composition, excipients, hardness/disintegration profile, or bioavailability-enhancing design.
- Method-of-use patents for specific dosing schedules or patient subgroups (less common for mature combinations).
- Manufacturing/process patents (granulation, compression parameters, coating, impurity control).
- Pediatric exclusivity or regulatory exclusivity (if any relevant product was newly approved or re-approved, generally not a major driver for older combination products).
Critical diligence for exclusivity and blocking coverage
- Orange Book listed patents for the exact NDC (tablet strengths and dosage form matter).
- Whether any listing is tied to drug substance versus drug product or method-of-use.
- Whether the patent is expired, set to expire, or only listed but not enforceable against an ANDA product.
- Whether any Paragraph IV challenges exist.
When does oxycodone and aspirin lose exclusivity in the US?
Featured snippet answer: For mature opioid/NSAID fixed combinations, exclusivity loss is usually already in effect for most SKUs due to prior approvals and the long lapse of unexpired patents. The actionable timing question is still driven by the Orange Book status of the specific NDC being evaluated: some strengths can retain later-listed formulation patents or process patents even if the core molecule is off-patent.
Exclusivity timeline mechanics (what governs generic entry)
- Patent expiration blocks ANDA approval until the earliest listed patent expires (or is successfully challenged and a court allows).
- Regulatory exclusivity (if present) can extend beyond patent expiration.
- Settlement agreements can delay generic launch even when a patent is challenged.
Investment implications of “already off-exclusivity”
If the specific oxycodone/aspirin SKU has no unexpired Orange Book patents for the NDC, the investment case becomes a margin-and-market-share story rather than an IP moat story, with key risks:
- Price compression from multi-source generics.
- Substitution away from opioid-containing fixed-dose products under payer and regulatory pressure.
- Supply constraints or product discontinuations that can create temporary revenue spikes but are not IP-protectable.
How many patents cover oxycodone and aspirin products and what is the practical strength?
Featured snippet answer: For long-established opioid/NSAID fixed combinations, the practical patent count is often low for enforceable blocking coverage because many formulations have either expired patents or have no meaningful differentiation from generic tablets. When patents exist, they are usually formulation/process and their enforceability depends on claim scope versus generic composition and manufacturing method.
How patent strength should be scored
For any specific product NDC:
- 1P blocking patents: remaining term and enforceability.
- Late-listed patents: whether listings were added to capture life-cycle changes and whether they overlap with the generic design.
- Litigation history: whether claims were asserted or invalidated.
- Freedom-to-operate: whether a generic can design around formulation/process claims.
What generic entry risks exist for oxycodone and aspirin tablets?
Featured snippet answer: The main generic entry risk is not just legal entry (ANDA approval), it is commercial entry: even if a court or patent blocks one competitor, multiple ANDAs can enter within a short window once exclusivity ends for each strength and dosage form.
ANDA launch patterns
- If a product is off-patent for composition/formulation, generic entrants typically launch at multiple strengths rapidly.
- If there is a late-life formulation/process patent, entrants may carve a design-around that avoids infringement while still meeting bioequivalence.
Operational and labeling risks
For opioid combinations, additional commercial risk drivers include:
- REMS-adjacent payer controls and prescribing limitations affecting demand.
- Product interruption risk (NSAID supply, opioid API availability, tablet manufacturing).
- Labeling changes reducing certain indications or patient usage.
What is the Orange Book status of oxycodone and aspirin?
Featured snippet answer: Orange Book status must be evaluated by NDC and dosage form. A single combination category can have multiple branded NDCs or discontinued SKUs. The investable result is: for each strength, confirm whether there are active Orange Book listings and whether those patents are expiring soon.
What to extract from the Orange Book
For each NDC strength:
- Patent number
- Patent type (drug substance, drug product, or method)
- Expiration date
- Exclusivity blocks (if any)
- Whether the listing is the basis of any ANDA Para IV
What patent litigation affects oxycodone and aspirin generics?
Featured snippet answer: Litigation materially affects launch timing only when it results in an injunction or a binding settlement that extends exclusivity beyond patent expiration. For mature combinations, the typical litigation pattern is either already resolved or limited to late-life formulation/process disputes.
What to search in litigation dockets
- Para IV notice events for the exact NDC and strength.
- Court outcomes: infringement vs invalidity vs non-infringement findings.
- Settlement agreements tied to launch dates and “carve-out” agreements.
- Consent judgments affecting FDA approval but also commercial launch.
How do oxycodone and aspirin compare with alternatives for analgesia investment?
Featured snippet answer: Oxycodone/aspirin competes on a narrow clinical niche versus oxycodone alone, other opioid/acetaminophen combinations, and non-opioid NSAID strategies. Commercial durability is constrained by opioid policy, payer formularies, and substitution by multi-source generics in adjacent categories.
Competitive substitutes investors should model
- Opioid monotherapy generics and branded ER products (where applicable).
- Opioid/acetaminophen fixed doses (often preferred due to dosing conventions and patient tolerance profiles).
- NSAID-only regimens and COX-2 selective options in lines of therapy that do not require opioid combination.
What is the FDA regulatory status of oxycodone and aspirin (ANDA/RLD pathway)?
Featured snippet answer: Most oxycodone/aspirin combinations are or have been on an ANDA pathway for generics once patents/exclusivity expired for each strength. The key investment regulatory detail is whether any currently marketed brand is an RLD with active Orange Book coverage or whether the market is already dominated by generics.
Regulatory diligence checklist
- Confirm the RLD status by NDC and active ingredient labeling.
- Identify whether current generics use:
- a bioequivalent ANDA,
- or a different dosage form/strength that could avoid direct substitution.
- Track any FDA labeling changes that reduce use.
Who are the major companies selling oxycodone and aspirin and how does that affect margins?
Featured snippet answer: Company lists and market share drive margins more than IP for mature combinations. Generics generally compress pricing, and margin resilience depends on supply reliability, manufacturing scale, and payer contracting terms.
What to model for margin durability
- Number of stocked sources per strength.
- Gross-to-net dynamics from rebates and wholesaler fees.
- Supply reliability and recall history (tablets with NSAID components can face distinct manufacturing hurdles).
- Contracting status with large PBMs.
Investment scenario: revenue drivers, downside risks, and timing
Revenue base assumptions that tend to hold for mature oxycodone/aspirin SKUs
- Demand is sensitive to opioid prescribing trends, payer tightening, and prescriber migration to other regimens.
- Fixed-dose opioid/NSAID combinations typically face substitution pressure from:
- opioid/acetaminophen options,
- NSAID monotherapy,
- and non-opioid strategies.
- Generics dominate once patents expire; returns then depend on manufacturing cost position and supply stability.
Downside risks that matter for capital allocation
- Patent-driven repricing is unlikely to be a core value driver unless a specific SKU has unexpired blocking patents or a live settlement extending launch.
- FDA labeling or policy constraints affecting opioids can reduce addressable demand even if legal exclusivity is present.
- Litigation can delay entry but often does not restore long-term pricing power once multiple generic sources are entrenched.
Timing triggers
- Orange Book expiration or settlement end dates for each NDC strength.
- ANDA approvals and launch timing by strength.
- Any supply disruption or discontinuation by dominant manufacturers that temporarily raises pricing but is not IP-protectable.
Key Takeaways
- Treat oxycodone/aspirin investment primarily as a generic market and policy-resilience thesis, not a new-IP thesis, unless a specific evaluated NDC still has active Orange Book blocking patents.
- The only defensible exclusivity and litigation timing work product is by exact NDC strength and dosage form, with Orange Book patent list and Para IV status driving generic launch probability.
- Margin durability is driven by number of competing stocked sources, gross-to-net contracting, and manufacturing reliability, with opioid and NSAID prescribing/policy constraints limiting category growth.
FAQs
- Which oxycodone/aspirin NDC strengths still have active Orange Book patents?
- Do Paragraph IV challenges exist for oxycodone and aspirin ANDAs by strength and NDC?
- What are the common patent types asserted in oxycodone/aspirin tablet cases (formulation vs method-of-use vs process)?
- How do opioid prescribing restrictions and payer formulary changes typically affect fixed-dose opioid/NSAID combination demand?
- What launch delays are caused by settlements or injunctions for generic oxycodone/aspirin tablets?
References
No sources cited.
